Clinical Trial Update: A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis

View source ↗

Summary

A completed real-world study conducted in Spain evaluating the use of siponimod for secondary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Siponimod (siponimod)

Snippet

Sponsor: Novartis | Conditions: Secondary Progressive Multiple Sclerosis | Status: COMPLETED